Sexually Transmitted Diseases

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.

Two phase 3 studies presented at IAS 2019 evaluated a switch to B/F/TAF among individuals virologically suppressed on other HIV treatment regimens.

The team assessed program engagement, medication refills, and self-reported 3-day adherence over 72 weeks, among the individuals who initiated PrEP.

The guidelines include a new section featuring recommendations for treating transgender people living with HIV.

Long-acting reservoir-style PrEP implants could help solve adherence issues.

PrEP awareness among these MSM rose from 60% to 90% from 2014 to 2017, and PrEP use increased from 6% to 35%.

New research assesses potential alternatives to a daily dose of emtricitabine/tenofovir. It finds mixed results.

The program combines PrEP administration along with evidence-based behavioral intervention to reduce HIV risk behavior for HIV-negative, opioid-dependent people who use drugs and are receiving treatment.

Interest in on-demand HIV pre-exposure prophylaxis may be increasing, according to a survey in Australia.

Investigators sought to identify potentially intervenable factors that affect mortality among PLWH in the city of San Francisco.

Getting PrEP into the hands of those who stand to gain the most from it, including women in sub-Saharan Africa remains a challenge.

The investigators used a combined approach of LASER ART and CRISPR-Cas9 to successfully eliminate replication-competent HIV-1 DNA from the genome of living mice.

The FDA approved the first darunavir-based single-tablet regimen for the treatment of HIV in July 2018. How is it working out for patients and providers alike?

Testing and information will be available at select Walgreens stores in more than 260 cities on National HIV Testing Day on Thursday between 10 am and 7 pm.

ACIP voted 10-to-4 to expand the recommended HPV vaccine “catch-up” age for men from 21 to 26, matching the existing guidelines for women.

The recommendation means more patients will be able to access PrEP at no cost. However, it likely won’t be enough to dramatically boost PrEP usage without other systemic advances.

The FDA has expanded the patient population and issued updated drug interactions, warnings, and precautions for Biktarvy.

A recent animal trial reveals that MK-8591 offers protection against SHIV at lower and more infrequent doses than current PrEP options, renewing hope for more choices in the future.

Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.

A phase 1 study demonstrated that pembrolizumab is appropriate for FDA-approved indications and clinical trials among people living with HIV and advanced cancer.

Failure to fill prescriptions is a common issue among adolescents diagnosed with sexually transmitted infections in emergency departments, according to a new research letter.

The HIV Medicine Association reports that the recommendation, once implemented in 2021, will require insurers to cover PrEP with no cost-sharing to patients.

Meeting goals to eliminate HIV, viral hepatitis, and sexually transmitted infections by 2030 will require accelerated efforts, according to a progress report from the WHO.

Very early introduction of ART may alter HIV immune response long term, with implications for development of effective vaccine.

Individuals at a higher risk of contracting HIV showed greater adherence to PrEP and moved toward less risky partnership types over time.

Nearly 500 children are infected with HIV after being put at risk due to poor medical practices in a country where violence against individuals living with HIV is still an issue.

A look at up-and-coming HIV drugs in development.

Following the launch of the campaign in March 2015, investigators saw a 77% increase in HIV testing compared with January and February of the same year in Beijing.

For the first time, patients with new HIV diagnoses have a 2-drug regimen option.